{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T08:39:25Z","timestamp":1782290365321,"version":"3.54.5"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1007\/s00228-023-03503-6","type":"journal-article","created":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T09:02:29Z","timestamp":1685610149000},"page":"897-913","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Population pharmacokinetic analyses of tacrolimus in non-transplant patients: a systematic review"],"prefix":"10.1007","volume":"79","author":[{"given":"Cheng-Bin","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-jia","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Ming","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-mei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,1]]},"reference":[{"key":"3503_CR1","doi-asserted-by":"crossref","unstructured":"Rauch MC, San Martin A, Ojeda D et al (2009) Tacrolimus causes a blockage of protein secretion which reinforces its immunosuppressive activity and also explains some of its toxic side-effects. Transpl Immunol 22(1\u20132):72\u201381","DOI":"10.1016\/j.trim.2009.07.001"},{"issue":"1","key":"3503_CR2","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1093\/ibd\/izz068","volume":"26","author":"B Wu","year":"2020","unstructured":"Wu B, Tong J, Ran Z (2020) Tacrolimus Therapy in Steroid-Refractory Ulcerative Colitis: A Review. Inflamm Bowel Dis 26(1):24\u201332","journal-title":"Inflamm Bowel Dis"},{"issue":"2","key":"3503_CR3","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1111\/bcp.14174","volume":"86","author":"GX Hao","year":"2020","unstructured":"Hao GX, Song LL, Zhang DF et al (2020) Off-label use of tacrolimus in children with glomerular disease: Effectiveness, safety and pharmacokinetics. Br J Clin Pharmacol 86(2):274\u2013284","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"3503_CR4","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1097\/TP.0000000000003350","volume":"105","author":"SC Ong","year":"2021","unstructured":"Ong SC, Gaston RS (2021) Thirty Years of Tacrolimus in Clinical Practice. Transplantation 105(3):484\u2013495","journal-title":"Transplantation"},{"issue":"9","key":"3503_CR5","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1111\/ajt.13309","volume":"15","author":"MA Sikma","year":"2015","unstructured":"Sikma MA, van Maarseveen EM, van de Graaf EA et al (2015) Pharmacokinetics and Toxicity of Tacrolimus Early After Heart and Lung Transplantation. Am J Transplant 15(9):2301\u20132313","journal-title":"Am J Transplant"},{"issue":"6","key":"3503_CR6","doi-asserted-by":"publisher","first-page":"513","DOI":"10.2174\/1389200219666180129151948","volume":"19","author":"M Yu","year":"2018","unstructured":"Yu M, Liu M, Zhang W et al (2018) Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of Tacrolimus in Kidney Transplantation. Curr Drug Metab 19(6):513\u2013522","journal-title":"Curr Drug Metab"},{"issue":"2","key":"3503_CR7","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.trre.2015.01.002","volume":"29","author":"N Shuker","year":"2015","unstructured":"Shuker N, van Gelder T, Hesselink DA (2015) Intra-patient variability in tacrolimus exposure: causes, consequences for clinical management. Transplant Rev (Orlando) 29(2):78\u201384","journal-title":"Transplant Rev (Orlando)"},{"issue":"2","key":"3503_CR8","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/aps.2014.110","volume":"36","author":"YX Lu","year":"2015","unstructured":"Lu YX, Su QH, Wu KH et al (2015) A population pharmacokinetic study of tacrolimus in healthy Chinese volunteers and liver transplant patients. Acta Pharmacol Sin 36(2):281\u2013288","journal-title":"Acta Pharmacol Sin"},{"issue":"1","key":"3503_CR9","doi-asserted-by":"publisher","first-page":"473","DOI":"10.2147\/DDDT.S41349","volume":"9","author":"CJ Li","year":"2015","unstructured":"Li CJ, Li L (2015) Tacrolimus in preventing transplant rejection in Chinese patients\u2013optimizing use. Drug Des Devel Ther 9(1):473\u2013485","journal-title":"Drug Des Devel Ther"},{"key":"3503_CR10","doi-asserted-by":"crossref","unstructured":"Merc\u00e8 B, Teun VG, Anders \u00c5 et al (2019) Therapeutic drug monitoring of tacrolimus-personalized therapy: second consensus report. Ther Drug Monit 41(3):261\u2013307","DOI":"10.1097\/FTD.0000000000000640"},{"key":"3503_CR11","doi-asserted-by":"crossref","unstructured":"Abdel Jalil M, Abdullah N, Alsous M et al (2021) Population pharmacokinetic studies of digoxin in adult patients: a systematic review. Eur J Drug Metab Pharmacokinet 46(3):325\u2013342","DOI":"10.1007\/s13318-021-00672-6"},{"issue":"4","key":"3503_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/psp.2013.14","volume":"2","author":"DR Mould","year":"2013","unstructured":"Mould DR, Upton RN (2013) Basic concepts in population modeling, simulation, and model-based drug development-part 2: introduction to pharmacokinetic modeling methods. CPT Pharmacometrics Syst Pharmacol 2(4):e38","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"11","key":"3503_CR13","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1007\/s40262-016-0396-1","volume":"55","author":"E Brooks","year":"2016","unstructured":"Brooks E, Tett SE, Isbel NM et al (2016) Population Pharmacokinetic Modelling and Bayesian Estimation of Tacrolimus Exposure: Is this Clinically Useful for Dosage Prediction Yet? Clin Pharmacokinet 55(11):1295\u20131335","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"3503_CR14","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1002\/jcph.1325","volume":"59","author":"O Campagne","year":"2019","unstructured":"Campagne O, Mager DE, Tornatore KM (2019) Population Pharmacokinetics of Tacrolimus in Transplant Recipients: What Did We Learn About Sources of Interindividual Variabilities? J Clin Pharmacol 59(3):309\u2013325","journal-title":"J Clin Pharmacol"},{"issue":"11","key":"3503_CR15","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1007\/s40262-020-00922-x","volume":"59","author":"R Kirubakaran","year":"2020","unstructured":"Kirubakaran R, Stocker SL, Hennig S et al (2020) Population Pharmacokinetic Models of Tacrolimus in Adult Transplant Recipients: A Systematic Review. Clin Pharmacokinet 59(11):1357\u20131392","journal-title":"Clin Pharmacokinet"},{"issue":"12","key":"3503_CR16","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.1111\/bcp.14110","volume":"85","author":"TM Nanga","year":"2019","unstructured":"Nanga TM, Doan TTP, Marquet P et al (2019) Toward a robust tool for pharmacokinetic-based personalization of treatment with tacrolimus in solid organ transplantation: A model-based meta-analysis approach. Br J Clin Pharmacol 85(12):2793\u20132823","journal-title":"Br J Clin Pharmacol"},{"issue":"11","key":"3503_CR17","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1007\/s00467-015-3133-3","volume":"30","author":"A Jahan","year":"2015","unstructured":"Jahan A, Prabha R, Chaturvedi S et al (2015) Clinical efficacy and pharmacokinetics of tacrolimus in children with steroid-resistant nephrotic syndrome. Pediatr Nephrol 30(11):1961\u20131967","journal-title":"Pediatr Nephrol"},{"issue":"15","key":"3503_CR18","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.2217\/pgs-2019-0090","volume":"20","author":"H Lingfei","year":"2019","unstructured":"Lingfei H, Junyan W, Jufei Y et al (2019) Impact of CYP3A4\/5 and ABCB1 polymorphisms on tacrolimus exposure and response in pediatric primary nephrotic syndrome. Pharmacogenomics 20(15):1071\u20131083","journal-title":"Pharmacogenomics"},{"issue":"1","key":"3503_CR19","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s00228-020-02977-y","volume":"77","author":"J Wang","year":"2021","unstructured":"Wang J, Huang L, Gao P et al (2021) Diltiazem on tacrolimus exposure and dose sparing in Chinese pediatric primary nephrotic syndrome: impact of CYP3A4, CYP3A5, ABCB1, and SLCO1B3 polymorphisms. Eur J Clin Pharmacol 77(1):71\u201377","journal-title":"Eur J Clin Pharmacol"},{"issue":"9","key":"3503_CR20","doi-asserted-by":"publisher","first-page":"840","DOI":"10.3109\/00498254.2015.1021733","volume":"45","author":"L Zhu","year":"2015","unstructured":"Zhu L, Yang J, Zhang Y et al (2015) Effects of CYP3A5 genotypes, ABCB1 C3435T and G2677T\/A polymorphism on pharmacokinetics of Tacrolimus in Chinese adult liver transplant patients. Xenobiotica 45(9):840\u2013846","journal-title":"Xenobiotica"},{"issue":"10","key":"3503_CR21","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.2147\/TCRM.S184376","volume":"14","author":"E Ji","year":"2018","unstructured":"Ji E, Kim MG, Oh JM (2018) CYP3A5 genotype-based model to predict tacrolimus dosage in the early postoperative period after living donor liver transplantation. Ther Clin Risk Manag 14(10):2119\u20132126","journal-title":"Ther Clin Risk Manag"},{"issue":"6","key":"3503_CR22","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1111\/j.1365-2125.2007.02888.x","volume":"64","author":"M Antignac","year":"2007","unstructured":"Antignac M, Barrou B, Farinotti R et al (2007) Population pharmacokinetics and bioavailability of tacrolimus in kidney transplant patients. Br J Clin Pharmacol 64(6):750\u2013757","journal-title":"Br J Clin Pharmacol"},{"issue":"9","key":"3503_CR23","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1097\/00007890-200105150-00021","volume":"71","author":"S Tuteja","year":"2001","unstructured":"Tuteja S, Alloway RR, Johnson JA et al (2001) The effect of gut metabolism on tacrolimus bioavailability in renaltransplant recipients1,2. Transplantation 71(9):1303\u20131307","journal-title":"Transplantation"},{"issue":"7","key":"3503_CR24","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s40262-015-0236-8","volume":"54","author":"S Kanji","year":"2015","unstructured":"Kanji S, Hayes M, Ling A et al (2015) Reporting Guidelines for Clinical Pharmacokinetic Studies: The ClinPK Statement. Clin Pharmacokinet 54(7):783\u2013795","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"3503_CR25","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1111\/j.1365-2125.2007.02975.x","volume":"64","author":"C Dartois","year":"2007","unstructured":"Dartois C, Brendel K, Comets E et al (2007) Overview of model-building strategies in population PK\/PD analyses: 2002\u20132004 literature survey. Br J Clin Pharmacol 64(5):603\u2013612","journal-title":"Br J Clin Pharmacol"},{"key":"3503_CR26","doi-asserted-by":"crossref","unstructured":"Abdel Jalil MH, Abdullah N, Alsous MM et al (2020) A systematic review of population pharmacokinetic analyses of digoxin in the paediatric population. Br J Clin Pharmacol 86(7):1267\u20131280","DOI":"10.1111\/bcp.14272"},{"key":"3503_CR27","doi-asserted-by":"crossref","unstructured":"Li Z-R, Wang C-Y, Zhu X et al (2021) Population pharmacokinetics of levetiracetam: a systematic review. Clin Pharmacokinet 60(3):305\u2013318","DOI":"10.1007\/s40262-020-00963-2"},{"issue":"5","key":"3503_CR28","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1097\/FTD.0000000000001008","volume":"44","author":"L Minghao","year":"2022","unstructured":"Minghao L, Minglu W, Xu Z et al (2022) Tacrolimus Population Pharmacokinetic Model in Adult Chinese Patients with Nephrotic Syndrome and Dosing Regimen Identification Using Monte Carlo Simulations. Ther Drug Monit 44(5):615\u2013624","journal-title":"Ther Drug Monit"},{"issue":"9","key":"3503_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.107827","volume":"98","author":"L Li","year":"2021","unstructured":"Li L, Zhu M, Li DY et al (2021) Dose tailoring of tacrolimus based on a non-linear pharmacokinetic model in children with refractory nephrotic syndrome. Int Immunopharmacol 98(9):107827","journal-title":"Int Immunopharmacol"},{"issue":"2","key":"3503_CR30","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1111\/jcpt.13072","volume":"45","author":"X Chen","year":"2020","unstructured":"Chen X, Wang D, Xu H et al (2020) Initial dose optimization of tacrolimus for children with systemic lupus erythematosus based on the CYP3A5 polymorphism and coadministration with Wuzhi capsule. J Clin Pharm Ther 45(2):309\u2013317","journal-title":"J Clin Pharm Ther"},{"issue":"5","key":"3503_CR31","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1080\/00498254.2019.1669844","volume":"50","author":"X Chen","year":"2020","unstructured":"Chen X, Wang DD, Xu H et al (2020) Optimization of initial dosing scheme of tacrolimus in pediatric refractory nephrotic syndrome patients based on CYP3A5 genotype and coadministration with wuzhi-capsule. Xenobiotica 50(5):606\u2013613","journal-title":"Xenobiotica"},{"issue":"3","key":"3503_CR32","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s11095-019-2579-6","volume":"36","author":"T Lu","year":"2019","unstructured":"Lu T, Zhu X, Xu S et al (2019) Dosage Optimization Based on Population Pharmacokinetic Analysis of Tacrolimus in Chinese Patients with Nephrotic Syndrome. Pharm Res 36(3):45","journal-title":"Pharm Res"},{"issue":"2","key":"3503_CR33","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.3892\/etm.2020.8821","volume":"20","author":"X Chen","year":"2020","unstructured":"Chen X, Wang D, Xu H et al (2020) Population pharmacokinetics model and initial dose optimization of tacrolimus in children and adolescents with lupus nephritis based on real world data. Exp Ther Med 20(2):1423\u20131430","journal-title":"Exp Ther Med"},{"issue":"6","key":"3503_CR34","first-page":"4653","volume":"18","author":"D Wang","year":"2019","unstructured":"Wang D, Chen X, Xu H et al (2019) Population pharmacokinetics of tacrolimus in pediatric patients with systemic-onset juvenile idiopathic arthritis: Initial dosage recommendations. Exp Ther Med 18(6):4653\u20134660","journal-title":"Exp Ther Med"},{"issue":"5","key":"3503_CR35","first-page":"4023","volume":"17","author":"D Wang","year":"2019","unstructured":"Wang D, Lu J, Li Q et al (2019) Population pharmacokinetics of tacrolimus in pediatric refractory nephrotic syndrome and a summary of other pediatric disease models. Exp Ther Med 17(5):4023\u20134031","journal-title":"Exp Ther Med"},{"issue":"11","key":"3503_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.942129","volume":"13","author":"Q Huang","year":"2022","unstructured":"Huang Q, Lin X, Wang Y et al (2022) Tacrolimus pharmacokinetics in pediatric nephrotic syndrome: A combination of population pharmacokinetic modelling and machine learning approaches to improve individual prediction. Front Pharmacol 13(11):942129","journal-title":"Front Pharmacol"},{"issue":"4","key":"3503_CR37","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1111\/jcpt.12707","volume":"43","author":"DD Wang","year":"2018","unstructured":"Wang DD, Lu JM, Li Q et al (2018) Population pharmacokinetics of tacrolimus in paediatric systemic lupus erythematosus based on real-world study. J Clin Pharm Ther 43(4):476\u2013483","journal-title":"J Clin Pharm Ther"},{"issue":"1","key":"3503_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2019.105199","volume":"143","author":"L Huang","year":"2020","unstructured":"Huang L, Liu Y, Jiao Z et al (2020) Population pharmacokinetic study of tacrolimus in pediatric patients with primary nephrotic syndrome: A comparison of linear and nonlinear Michaelis-Menten pharmacokinetic model. European journal of pharmaceutical sciences\u202f: official journal of the European Federation for Pharmaceutical Sciences 143(1):105199","journal-title":"European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences"},{"issue":"3","key":"3503_CR39","doi-asserted-by":"publisher","first-page":"125","DOI":"10.5414\/CP203355","volume":"57","author":"X Wang","year":"2019","unstructured":"Wang X, Han Y, Chen C et al (2019) Population pharmacokinetics and dosage optimization of tacrolimus in pediatric patients with nephrotic syndrome. Int J Clin Pharmacol Ther 57(3):125\u2013134","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"8","key":"3503_CR40","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1111\/bcp.13605","volume":"84","author":"GX Hao","year":"2018","unstructured":"Hao GX, Huang X, Zhang DF et al (2018) Population pharmacokinetics of tacrolimus in children with nephrotic syndrome. Br J Clin Pharmacol 84(8):1748\u20131756","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"3503_CR41","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s13318-020-00609-5","volume":"45","author":"J Liu","year":"2020","unstructured":"Liu J, Guo YP, Jiao Z et al (2020) Population Pharmacokinetic Analysis of Tacrolimus in Adult Chinese Patients with Myasthenia Gravis: A Prospective Study. Eur J Drug Metab Pharmacokinet 45(4):453\u2013466","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"8","key":"3503_CR42","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1038\/aps.2016.174","volume":"38","author":"YS Chen","year":"2017","unstructured":"Chen YS, Liu ZQ, Chen R et al (2017) Population pharmacokinetic analysis of tacrolimus in Chinese myasthenia gravis patients. Acta Pharmacol Sin 38(8):1195\u20131204","journal-title":"Acta Pharmacol Sin"},{"issue":"1","key":"3503_CR43","first-page":"110","volume":"1","author":"MK Shim","year":"2016","unstructured":"Shim MK, Kim JM, Choi KE et al (2016) Population pharmacokinetic analysis of oral tacrolimus in patients with glomerulonephritis. Int J Clin Pharmacol Ther 1(1):110\u2013115","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"5","key":"3503_CR44","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1111\/bcp.12830","volume":"81","author":"CY Zhao","year":"2016","unstructured":"Zhao CY, Jiao Z, Mao JJ et al (2016) External evaluation of published population pharmacokinetic models of tacrolimus in adult renal transplant recipients. Br J Clin Pharmacol 81(5):891\u2013907","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"3503_CR45","doi-asserted-by":"publisher","first-page":"358","DOI":"10.3389\/fphar.2017.00358","volume":"8","author":"JB Woillard","year":"2017","unstructured":"Woillard JB, Mourad M, Neely M et al (2017) Tacrolimus Updated Guidelines through popPK Modeling: How to Benefit More from CYP3A Pre-emptive Genotyping Prior to Kidney Transplantation. Front Pharmacol 8(8):358","journal-title":"Front Pharmacol"},{"issue":"1","key":"3503_CR46","volume":"2014","author":"L Zhu","year":"2014","unstructured":"Zhu L, Wang H, Sun X et al (2014) The Population Pharmacokinetic Models of Tacrolimus in Chinese Adult Liver Transplantation Patients. J Pharm (Cairo) 2014(1):713650","journal-title":"J Pharm (Cairo)"},{"key":"3503_CR47","doi-asserted-by":"crossref","unstructured":"Sam WJ, Tham LS, Holmes MJ et al (2006) Population pharmacokinetics of tacrolimus in whole blood and plasma in asian liver transplant patients. Clin Pharmacokinet 45(1):59\u201375","DOI":"10.2165\/00003088-200645010-00004"},{"issue":"2","key":"3503_CR48","doi-asserted-by":"publisher","first-page":"101","DOI":"10.12793\/tcp.2017.25.2.101","volume":"25","author":"J Guk","year":"2017","unstructured":"Guk J, Chae D, Park K (2017) Relationship between body weight and postmenstrual age in a Korean pediatric population. Transl Clin Pharmacol 25(2):101\u2013105","journal-title":"Transl Clin Pharmacol"},{"issue":"1","key":"3503_CR49","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1146\/annurev.pharmtox.48.113006.094708","volume":"48","author":"BJ Anderson","year":"2008","unstructured":"Anderson BJ, Holford NH (2008) Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol 48(1):303\u2013332","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"1","key":"3503_CR50","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/cpt.113","volume":"98","author":"KA Birdwell","year":"2015","unstructured":"Birdwell KA, Decker B, Barbarino JM et al (2015) Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing. Clin Pharmacol Ther 98(1):19\u201324","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"3503_CR51","doi-asserted-by":"publisher","first-page":"8","DOI":"10.4103\/ijot.ijot_4_20","volume":"14","author":"S Bansal","year":"2020","unstructured":"Bansal S (2020) Therapeutic drug monitoring of tacrolimus in kidney transplantation. Indian Journal of Transplantation 14(1):8\u201314","journal-title":"Indian Journal of Transplantation"},{"issue":"2","key":"3503_CR52","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1515\/dmpt-2016-0036","volume":"32","author":"EY Tamashiro","year":"2017","unstructured":"Tamashiro EY, Felipe CR, Genvigir FDV et al (2017) Influence of CYP3A4 and CYP3A5 polymorphisms on tacrolimus and sirolimus exposure in stable kidney transplant recipients. Drug Metab Pers Ther 32(2):89\u201395","journal-title":"Drug Metab Pers Ther"},{"issue":"1","key":"3503_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2021.146007","volume":"809","author":"Y Dong","year":"2022","unstructured":"Dong Y, Xu Q, Li R et al (2022) CYP3A7, CYP3A4, and CYP3A5 genetic polymorphisms in recipients rather than donors influence tacrolimus concentrations in the early stages after liver transplantation. Gene 809(1):146007","journal-title":"Gene"},{"issue":"32","key":"3503_CR54","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.cca.2015.03.021","volume":"445","author":"T Naito","year":"2015","unstructured":"Naito T, Mino Y, Aoki Y et al (2015) ABCB1 genetic variant and its associated tacrolimus pharmacokinetics affect renal function in patients with rheumatoid arthritis. Clin Chim Acta 445(32):79\u201384","journal-title":"Clin Chim Acta"},{"issue":"7","key":"3503_CR55","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1124\/dmd.112.050302","volume":"41","author":"H Wei","year":"2013","unstructured":"Wei H, Tao X, Di P et al (2013) Effects of traditional chinese medicine Wuzhi capsule on pharmacokinetics of tacrolimus in rats. Drug Metab Dispos 41(7):1398\u20131403","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"3503_CR56","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1124\/dmd.113.053892","volume":"42","author":"XL Qin","year":"2014","unstructured":"Qin XL, Chen X, Wang Y et al (2014) In vivo to in vitro effects of six bioactive lignans of Wuzhi tablet (Schisandra sphenanthera extract) on the CYP3A\/P-glycoprotein-mediated absorption and metabolism of tacrolimus. Drug Metab Dispos 42(1):193\u2013199","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"3503_CR57","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/j.phymed.2013.12.006","volume":"21","author":"XL Qin","year":"2014","unstructured":"Qin XL, Chen X, Zhong GP et al (2014) Effect of Tacrolimus on the pharmacokinetics of bioactive lignans of Wuzhi tablet (Schisandra sphenanthera extract) and the potential roles of CYP3A and P-gp. Phytomedicine 21(5):766\u2013772","journal-title":"Phytomedicine"},{"issue":"1","key":"3503_CR58","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.coph.2015.07.002","volume":"24","author":"VJ Lempers","year":"2015","unstructured":"Lempers VJ, Martial LC, Schreuder MF et al (2015) Drug-interactions of azole antifungals with selected immunosuppressants in transplant patients: strategies for optimal management in clinical practice. Curr Opin Pharmacol 24(1):38\u201344","journal-title":"Curr Opin Pharmacol"},{"key":"3503_CR59","doi-asserted-by":"crossref","unstructured":"Zahir H, McLachlan AJ, Nelson A et al (2005) Population pharmacokinetic estimation of tacrolimus apparent clearance in adult liver transplant recipients. Ther Drug Monit 27(4):422\u2013430","DOI":"10.1097\/01.ftd.0000170029.36573.a0"},{"key":"3503_CR60","doi-asserted-by":"crossref","unstructured":"Press RR, Ploeger BA, Den Hartigh J et al (2009) Explaining variability in tacrolimus pharmacokinetics to optimize early exposure in adult kidney transplant recipients. Ther Drug Monit 31(2):187\u2013197","DOI":"10.1097\/FTD.0b013e31819c3d6d"},{"issue":"7","key":"3503_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105610","volume":"169","author":"ML Wang","year":"2021","unstructured":"Wang ML, Tao YY, Sun XY et al (2021) Estrogen profile- and pharmacogenetics-based lamotrigine dosing regimen optimization: Recommendations for pregnant women with epilepsy. Pharmacol Res 169(7):105610","journal-title":"Pharmacol Res"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-023-03503-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-023-03503-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-023-03503-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T14:35:46Z","timestamp":1702564546000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-023-03503-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,1]]},"references-count":61,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["3503"],"URL":"https:\/\/doi.org\/10.1007\/s00228-023-03503-6","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,1]]},"assertion":[{"value":"17 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}